OverviewSuggest Edit

GenMark Diagnostics is a provider of automated, multiplex molecular diagnostic testing systems. The Company develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.  It offers four Food and Drug Administration -cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. GenMark also offers a Hepatitis C genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only. 

TypePublic
Founded2010
HQCarlsbad, CA, US
Websitegenmarkdx.com
Employee Ratings2.9
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)437(-8%)
Job Openings63
Revenue (FY, 2020)$171.6 M(+95%)
Share Price (Apr 2021)$24
Cybersecurity ratingBMore

Key People/Management at GenMark Diagnostics

Scott Mendel

Scott Mendel

President and Chief Executive Officer
Michael Gleeson

Michael Gleeson

Senior Vice President, Corporate Accounts
Johnny Ek

Johnny Ek

Chief Financial Officer
Wade Stevenson

Wade Stevenson

Senior Vice President, North America Sales
Eric Stier

Eric Stier

Senior Vice President, General Counsel and Secretary
Scott O'Brien

Scott O'Brien

Senior Vice President, Global Marketing and International Sales
Show more

GenMark Diagnostics Office Locations

GenMark Diagnostics has offices in Carlsbad, Albany, Atlanta, Birmingham and in 29 other locations
Carlsbad, CA, US (HQ)
5964 La Place Ct
Albany, NY, US
Albany, NY, USA
Atlanta, GA, US
Atlanta, GA, USA
Birmingham, AL, US
Birmingham, AL, USA
Boston, MA, US
Boston, MA, USA
Bristol, TN, US
Bristol, TN, USA
Show all (33)

GenMark Diagnostics Financials and Metrics

GenMark Diagnostics Revenue

Embed Graph
View revenue for all periods
GenMark Diagnostics's revenue was reported to be $171.55 m in FY, 2020
USD

Revenue (FY, 2020)

171.6m

Gross profit (FY, 2020)

67.9m

Gross profit margin (FY, 2020), %

39.6%

Net income (FY, 2020)

(18.6m)

EBIT (FY, 2020)

(11.1m)

Market capitalization (26-Apr-2021)

1.8b

Closing stock price (26-Apr-2021)

24.0

Cash (31-Dec-2020)

40.6m

EV

1.8b
GenMark Diagnostics's current market capitalization is $1.8 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019FY, 2020

Revenue

5.0m20.5m27.4m30.6m39.4m49.3m52.5m88.0m171.6m

Revenue growth, %

12%29%25%

Cost of goods sold

6.2m11.6m15.9m13.1m15.3m19.7m32.5m59.4m103.6m

Gross profit

(1.2m)8.8m11.5m17.5m24.1m29.6m20.0m28.6m67.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

901.0k1.3m2.2m3.6m5.3m11.1m5.2m4.6m7.9m6.6m6.3m10.1m7.6m8.5m11.1m12.5m10.8m12.5b12.4m11.6m14.9m15.8m18.4m20.9m38.7m40.1m

Cost of goods sold

1.3m1.8m1.7m2.2m3.0m5.0m3.2m4.1m3.7m3.2m2.7m4.0m3.3m3.4m4.4m4.7m4.4m6.4b7.5m7.4m10.5m10.2m11.8m13.9m22.6m24.2m

Gross profit

(393.0k)(469.0k)472.0k1.4m2.2m6.1m2.0m499.0k4.2m3.4m3.6m6.1m4.4m5.1m6.7m7.8m6.5m6.2b4.9m4.2m4.4m5.6m6.6m7.1m16.2m15.9m

Gross profit Margin, %

(44%)(36%)22%40%42%55%39%11%53%51%57%61%57%60%60%62%60%49%40%36%30%36%36%34%42%40%
Annual
USDY, 2009Y, 2010Y, 2011FY, 2011Y, 2012FY, 2012Y, 2013FY, 2013FY, 2014Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2019FY, 2020

Cash

16.5m51.3m25.3m25.3m51.3m51.3m35.7m35.7m36.9m36.9m35.4m35.4m16.0m26.8m44.4m40.6m

Accounts Receivable

1.1m3.2m2.9m4.9m6.8m10.7m16.8m20.8m

Prepaid Expenses

322.0k226.0k552.0k575.0k591.0k1.8m1.9m2.7m

Inventories

2.2m2.0m2.1m2.1m2.1m2.1m3.1m3.1m3.1m10.9m11.3m21.3m
Show all financial metrics

GenMark Diagnostics Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents Issued

130120100

Patents Pending

253530
Show all operating metrics

GenMark Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

GenMark Diagnostics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

GenMark Diagnostics Online and Social Media Presence

Embed Graph

GenMark Diagnostics Company Culture

  • Overall Culture

    B

    71/100

  • CEO Rating

    F

    44/100

  • Compensation

    C+

    70/100

Learn more on Comparably

GenMark Diagnostics News and Updates

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GenMark Diagnostics, Inc. Buyout

WILMINGTON, Del., March 15, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GenMark Diagnostics, Inc. (“GenMark”) (NASDAQ GM: GNMK) regarding possible breaches of fiduciary duties and other violations of law related to GenMark’s agreement to be acquired by Roche Hol…

Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

             Basel, 15 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics (NASDAQ: GNMK) today announced that they have entered into a definitive merger agreement for Roche to fully acquire GenMark at a price of US$ 24.05 per share in an all-cash transaction. This corresponds to…

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health…

GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum

CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTec…

GenMark Diagnostics Reports Fourth Quarter and Full Year 2019 Results

CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2019.
Show more

GenMark Diagnostics Blogs

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results Content Import Thu, 02/25/2021 - 16:08 GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results February 25, 2021 This release is a backfill from a News Wire Ear…

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

CARLSBAD, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020 .

GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis

CARLSBAD, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 ( RP2 ) is predicted to detect known SARS-CoV-2 variants

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 Content Import Thu, 02/11/2021 - 16:18 GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 February 11, 2021 …
Show more

GenMark Diagnostics Frequently Asked Questions

  • When was GenMark Diagnostics founded?

    GenMark Diagnostics was founded in 2010.

  • Who are GenMark Diagnostics key executives?

    GenMark Diagnostics's key executives are Scott Mendel, Michael Gleeson and Johnny Ek.

  • How many employees does GenMark Diagnostics have?

    GenMark Diagnostics has 437 employees.

  • What is GenMark Diagnostics revenue?

    Latest GenMark Diagnostics annual revenue is $171.6 m.

  • What is GenMark Diagnostics revenue per employee?

    Latest GenMark Diagnostics revenue per employee is $392.6 k.

  • Who are GenMark Diagnostics competitors?

    Competitors of GenMark Diagnostics include Abaxis, Chiesi France and Medical Pharmacies.

  • Where is GenMark Diagnostics headquarters?

    GenMark Diagnostics headquarters is located at 5964 La Place Ct, Carlsbad.

  • Where are GenMark Diagnostics offices?

    GenMark Diagnostics has offices in Carlsbad, Albany, Atlanta, Birmingham and in 29 other locations.

  • How many offices does GenMark Diagnostics have?

    GenMark Diagnostics has 33 offices.